AcouSort (ACOU) Q2 2026 earnings summary

Executive summary

• Achieved 36% year-over-year net sales growth in Q2 2026, driven by new collaborations and product sales.

• Expanded commercial activities with key installations and participation in major industry events in the US, Europe, and Asia.

• Focused on diagnostics, cell therapy, and lab automation markets, leveraging OEM partnerships and research collaborations.

Financial highlights

• Q2 2026 net sales: TSEK 2,116 (up from 1,551); H1 2026 net sales: TSEK 4,263 (up from 3,146) year-over-year.

• Q2 2026 result before tax: TSEK -3,532 (Q2 2025: -2,809); H1 2026 result before tax: TSEK -5,901 (H1 2025: -6,831).

• Equity ratio at June 30, 2026: 46% (down from 81%); cash and cash equivalents: TSEK 9,482.

• Operating result for Q2 2026: TSEK -3,613 (Q2 2025: -2,487); H1 2026: TSEK -6,661 (H1 2025: -5,820).

• Result per share H1 2026: SEK -0.28 (H1 2025: -0.41).

Outlook and guidance

• Plans to solidify market positions in diagnostics, cell therapy, and lab automation through strategic partnerships.

• Sufficient liquidity projected into Q1 2027, with ongoing efforts to secure additional institutional or strategic funding.

• Continued focus on expanding OEM collaborations and advancing core technology.